Key facts
- This page summarizes Jay Pepose's Form 4 filing for Ocuphire Pharma, Inc. (IRD).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 06 Jul 2022, 17:36.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Award
| Id | Content |
|---|---|
| F1 | The Reporting Person was granted shares of common stock in lieu of cash for board services for the second half of 2022. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.02 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to July 1, 2022. |